BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
3.500
0.00 (0.00%)
At close: Oct 30, 2025, 4:00 PM EDT
3.410
-0.090 (-2.57%)
After-hours: Oct 30, 2025, 6:21 PM EDT
BioLineRx Employees
BioLineRx had 28 employees as of December 31, 2024. The number of employees decreased by 51 or -64.56% compared to the previous year.
Employees
28
Change (1Y)
-51
Growth (1Y)
-64.56%
Revenue / Employee
$616,107
Profits / Employee
-$279,357
Market Cap
16.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | -51 | -64.56% |
| Dec 31, 2023 | 79 | 30 | 61.22% |
| Dec 31, 2022 | 49 | 11 | 28.95% |
| Dec 31, 2021 | 38 | 0 | - |
| Dec 31, 2020 | 38 | -4 | -9.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BLRX News
- 4 weeks ago - BioLineRx Ltd. - Special Call - Seeking Alpha
- 4 weeks ago - BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers - PRNewsWire
- 2 months ago - BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 - PRNewsWire
- 5 months ago - Why Is Nano-Cap BioLineRx Stock Surging On Friday? - Benzinga
- 5 months ago - BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting - PRNewsWire
- 5 months ago - BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript - Seeking Alpha